Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial

Lee, Chia-Lin; Wang, Jun‐Sing

doi:10.1111/ijcp.13450

Cited by 14 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BP trajectory is helpful for capturing the dynamic change of BP within a certain period and visualizing the direction and size of BP variability. Recent longitudinal studies suggest that subgroups with distinct trajectories of BP change may be associated with a variety of clinical outcomes such as cardiovascular events [ 15 – 18 ], stroke [ 18 , 19 ], and all-cause mortality [ 17 , 18 , 20 ]. Given the close association between the cardiovascular and cerebrovascular burden and dementia [ 21 , 22 ], we hypothesized that BP trajectory patterns would have predictive significance for the risk of subsequent dementia outcomes.…”

Section: Introductionmentioning

confidence: 99%

Trajectory patterns of blood pressure change up to six years and the risk of dementia: a nationwide cohort study

Cheng

et al. 2021

Aging

View full text Add to dashboard Cite

The present study aimed to investigate the associations between the trajectory of blood pressure (BP) change and the risk of subsequent dementia and to explore the differences in age, gender, and hypertension subgroups. We included 10,660 participants aged ≥ 60 years from 1998 to 2018 waves of the Chinese Longitudinal Healthy Longevity Survey. Latent growth mixture models were used to estimate BP trajectories. Cox-proportional hazard models were used to analyze the effects of BP trajectories on the risk of dementia. According to the results, stabilized systolic BP (SBP) was found to be associated with a higher risk of dementia compared with normal SBP [adjusted hazard ratio (aHR): 1.62; 95% confidence interval (CI): 1.27-2.07] and elevated SBP (aHR: 2.22; 95% CI: 1.51-3.28) in and only in the subgroups of the oldest-old, women, and subjects without hypertension at baseline. Similarly, stabilized pulse pressure (PP) was associated with a higher risk of dementia compared with normal PP (aHR: 1.52; 95% CI: 1.24-1.88) and elevated PP (aHR: 2.12; 95% CI: 1.48-3.04) in and only in the subgroups of the oldest-old, women, and subjects with hypertension at baseline. These findings suggest that stabilized SBP and PP have predictive significance for the occurrence of dementia in late life, and the factors of age, gender, and late-life hypertension should be considered when estimating the risk of BP decline on dementia.

show abstract

Section: Introductionmentioning

confidence: 99%

Trajectory patterns of blood pressure change up to six years and the risk of dementia: a nationwide cohort study

Cheng

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…The number of patients in each trajectory group was set to exceed 3% of the study population. 21 , 22 The models were fitted using the SAS ProcTraj procedure. 21 Finally, four distinct HbA1c trajectories were identified in both of the standard and intensive treatment arms ( Figure 2 ).…”

Section: Methodsmentioning

confidence: 99%

HbA1c trajectory and cardiovascular outcomes: an analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study

Wang

Liu

Lee

2021

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Background: We investigated the associations between glycated hemoglobin (HbA1c) trajectories and cardiovascular outcomes using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Methods: We used HbA1c values within the first 2 years of treatment for modeling with a latent class growth model. Groups of HbA1c trajectories were modeled separately in the standard (group 1–group 4) and intensive (group 5–group 8) treatment arms. The primary outcome in the ACCORD study was a composite of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes. Effects of HbA1c trajectories on cardiovascular outcomes were analyzed using a Cox-proportional hazard model. Results: Baseline HbA1c levels for the eight trajectories (group 1–group 8) were 7.8 ± 0.8, 8.2 ± 0.9, 9.3 ± 1.1, 9.6 ± 1.2, 7.8 ± 0.7, 10.1 ± 0.8, 8.3 ± 0.7, and 9.5 ± 1.1%, respectively. The respective values after 2 years of treatment were 7.0 ± 0.6, 7.7 ± 0.7, 8.5 ± 0.9, 10.3 ± 1.3, 6.2 ± 0.4, 6.5 ± 0.6, 7.2 ± 0.6, and 8.5 ± 1.1%. After a median follow-up of 4.8 years, group 5 and group 6 had similar outcomes compared with group 1 (reference group). In contrast, group 3, group 4, and group 8 had higher risks of the primary composite outcome compared with group 1. Conclusion: HbA1c trajectory was associated with cardiovascular outcomes in type 2 diabetes patients with high cardiovascular risk.

show abstract

“…Power calculations were performed for the primary outcome variable, i.e., the between groups difference in systolic blood pressure. This showed that a total sample size of 45 will be necessary to provide 80% power to detect a minimally important clinical difference (MCID) of 6 mmHg between groups [ 40 ], with a projected standard deviation of 5.5 mmHg in each group [ 41 ], accounting for a loss to follow up rate of 10%.…”

Section: Methodsmentioning

confidence: 99%

Effects of Montmorency Tart Cherry and Blueberry Juice on Cardiometabolic Outcomes in Healthy Individuals: Protocol for a 3-Arm Placebo Randomized Controlled Trial

Sinclair

Shadwell

Dillon

et al. 2021

IJERPH

View full text Add to dashboard Cite

Cardiometabolic disease is recognized as the predominant cause of global mortality and healthcare expenditure. Whilst pharmaceutical interventions are effective in the short term, their long-term efficacy remain equivocal and their associated side-effects are concerning. Owing to their high levels of anthocyanins, Montmorency tart cherries and blueberries have been cited as potentially important natural treatment/preventative modalities for cardiometabolic disease. This study proposed a randomized controlled trial, aims to test the effects of consumption of Montmorency tart cherry and blueberry juice on cardiometabolic outcomes compared to placebo. This 20-day, parallel, single-blind, randomized, placebo-controlled trial will recruit 45 individuals, who will be assigned to receive 60 mL per day of either Montmorency tart cherry juice, blueberry juice or a cherry/blueberry flavoured placebo. The primary study outcome is the between-group difference in systolic blood pressure from baseline to post-intervention. Secondary outcome measures will be between-group differences in anthropometric, energy expenditure and substrate oxidation (during rest and physical activity), haematological, blood pressure/resting heart rate, psychological wellbeing and sleep efficacy indices. Statistical analysis will be conducted on an intention-to-treat basis. This study has been granted ethical approval by the University of Central Lancashire, Health Research Ethics Committee (ref: HEALTH 0016) and formally registered as a trial. Dissemination of the study findings from this investigation will be through publication in a leading peer-reviewed journal.

show abstract

Systolic blood pressure trajectory and cardiovascular outcomes: An analysis using data in the Systolic Blood Pressure Intervention Trial

Cited by 14 publications

References 37 publications

Trajectory patterns of blood pressure change up to six years and the risk of dementia: a nationwide cohort study

Trajectory patterns of blood pressure change up to six years and the risk of dementia: a nationwide cohort study

HbA1c trajectory and cardiovascular outcomes: an analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study

Effects of Montmorency Tart Cherry and Blueberry Juice on Cardiometabolic Outcomes in Healthy Individuals: Protocol for a 3-Arm Placebo Randomized Controlled Trial

Contact Info

Product

Resources

About